Dexfadrostat


CAS No. : 102676-87-9

(Synonyms: (R)-Fadrozole; (R)-CGS 16949A (free base); FAD286)

102676-87-9
Price and Availability of CAS No. : 102676-87-9
Size Price Stock
1mg $180 In-stock
5mg $400 In-stock
10mg $620 In-stock
25mg $1240 In-stock
50mg $1920 In-stock
100mg $2880 In-stock
200 mg Get quote
500 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-113986
M.Wt: 223.27
Formula: C14H13N3
Purity: >98 %
Solubility: DMSO : 110 mg/mL (ultrasonic)
Introduction of 102676-87-9 :

Dexfadrostat ((R)-Fadrozole) is an orally active and selective aromatase inhibitor, with human aromatase IC50 values of 6.4 nM. Dexfadrostat suppresses estrogen synthesis, reduces circulating estradiol levels and suppresses aldosterone production. Dexfadrostat can be used for the research of breast cancer, primary aldosteronism, and hypertension[1][2][3][4]. IC50 & Target:pIC50: 6.17 (human placental aromatase) In Vitro:Dexfadrostat (20 min) potently inhibits human placental aromatase in vitro with an IC50 of 6.4 nM[1].
Dexfadrostat potently inhibits rat ovarian aromatase in vitro[1]. In Vivo:Dexfadrostat (Compound 26a) (p.o.; single dose) potently inhibits androstenedione-induced uterine hypertrophy in immature female rats with an oral ED50 of 0.03 mg/kg[1].
Dexfadrostat (p.o.) reduces circulating estradiol levels and suppresses uterine weight in intact cyclic female rats without inducing adrenal hypertrophy at doses that maximally inhibit estrogen synthesis[1].
Dexfadrostat (p.o.; daily) exhibits potent antitumor efficacy in intact female rats with DMBA (HY-W011845)-induced mammary tumors[1].
Dexfadrostat (0.01 μmol/kg; p.o.; single dose) significantly inhibits ovarian estrogen synthesis in female rats[1].

Your information is safe with us.